Last reviewed 2026-05-13 · How we verify

TLN-372 in combination with cetuximab

Treeline Biosciences, Inc. · Phase 1 active Small molecule

TLN-372 in combination with cetuximab is a Small molecule drug developed by Treeline Biosciences, Inc.. It is currently in Phase 1 development.

At a glance

Generic name	TLN-372 in combination with cetuximab
Sponsor	Treeline Biosciences, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

TLN-372 in Advanced KRAS Mutant Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TLN-372 in combination with cetuximab CI brief — competitive landscape report
TLN-372 in combination with cetuximab updates RSS · CI watch RSS
Treeline Biosciences, Inc. portfolio CI

Frequently asked questions about TLN-372 in combination with cetuximab

What is TLN-372 in combination with cetuximab?

TLN-372 in combination with cetuximab is a Small molecule drug developed by Treeline Biosciences, Inc..

Who makes TLN-372 in combination with cetuximab?

TLN-372 in combination with cetuximab is developed by Treeline Biosciences, Inc. (see full Treeline Biosciences, Inc. pipeline at /company/treeline-biosciences-inc).

What development phase is TLN-372 in combination with cetuximab in?

TLN-372 in combination with cetuximab is in Phase 1.

Manufacturer: Treeline Biosciences, Inc. — full pipeline